Fact CheckerSign in

NCT06313944Recruiting

German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation

German (GE) Multicenter Prospective Data Collection (Registry) on Treatment With Transcranial Pulse Wave Stimulation (TPS) in Patients With Alzheimer's Disease (A)

Source: ClinicalTrials.gov · Last updated 13 Oct 2026

Brief summary (registry, in English)

This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.

Status (registry)
Recruiting
Study type
Observational
Enrollment
100 (estimated)
First submitted
8 Mar 2024
Start date
6 Aug 2025
Primary completion date
1 Oct 2027
Lead sponsor
Heinrich-Heine University, Duesseldorf
NCT number
NCT06313944

What you commit to

  • Study type: Observational
  • Planned participants: 100
  • From 6 Aug 2025 to the primary completion date, 1 Oct 2027
  • 6 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Relevant intracerebral pathologies not related to Alzheimer's disease, such as vascular encephalopathy Fazekas grade 3, tumors, vascular malformations, pregnancy, metal implants, CAA according to Boston criteria, Z.n. or during antibody therapy ii. Blood coagulation disorders or oral anticoagulation iii. Epilepsy iv. Medical conditions leading to non-compliance with the protocol

Who the study is looking for

  • Age = 18 to 85 ii. N\>=100, clinical Alzheimer's syndrome, defined by a gradually progressive change in memory function (for severity using the MMSE as a screening tool) and impairment of activities of daily living for more than six months iii. MRI scan, in vivo evidence from CSF and/or PET using the NIA-AA criteria, which categorize the underlying pathological processes based on biomarkers, should be added if possible, but are optional. These biomarkers are categorized as ß-amyloid deposition, pathological tau and neurodegeneration \[AT(N)\], which can be detected on imaging and in biofluids. If possible, patients with Alzheimer's disease (AD) or Alzheimer's continuum should be included.
  • TPS treatment in a center of a neurological or psychiatric specialist and performed under supervision of a specialist

Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (6)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Universitätsklinikum Bonn - Klinik für Parkinson, Schlaf- und Bewegungsstörungen
Coordinator of this site? Confirm its status
BonnGermanyNot yet recruiting
Hospital zum Heiligen Geist GmbH & Co KG Klinik für Neurologie und Neurorehabilitation
Coordinator of this site? Confirm its status
KempenGermanyWithdrawn
Neurologische Praxis Prof. Wojtecki
Coordinator of this site? Confirm its status
NeussGermanyRecruiting
Evangelische Krankenhausstiftung Oldenburg - Universitätsklinik für Neurologie
Coordinator of this site? Confirm its status
OldenburgGermanyRecruiting
Ernst von Bergmann Klinikum - Klinik für Neurologie und Klinische Neuropsychologie
Coordinator of this site? Confirm its status
PotsdamGermanyRecruiting
Praxis Dr. Schwarz
Coordinator of this site? Confirm its status
UlmGermanyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.